Boehringer announces positive cardiovascular outcomes for linagliptin. Credit: © Boehringer Ingelheim.

Boehringer Ingelheim has reported full data from the Phase III RE-SPECT ESUS clinical trial of its oral thrombin inhibitor Pradaxa (dabigatran etexilate) to prevent recurrent stroke in people with embolic stroke of undetermined source (ESUS).

The randomised, double-blind trial compared Pradaxa to acetylsalicylic acid (ASA) in a total of 5,390 patients across more than 40 countries.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The primary endpoint of the study was a clinically significant difference between the study drug and ASA on the risk of a recurrent stroke among post-stroke patients suffering with ESUS.

Data showed that the trial failed to meet the primary endpoint. A post-hoc analysis, however, revealed a treatment effect in favour of dabigatran after one year.

Safety analysis showed no significant difference in the risk of major bleeding between the dabigatran etexilate and ASA groups. Moreover, a comparable low risk for the most serious bleeding outcomes was observed.

Boehringer Ingelheim corporate vice-president and CardioMetabolic Medicine head Dr Waheed Jamal said: “The results from RE-SPECT ESUS provide highly interesting information, showing that dabigatran had a similar low risk of major bleeding compared to ASA in this high-risk population of post-stroke patients. This clearly reaffirms the positive risk-benefit profile of dabigatran.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company added that data from this trial expands the evidence supporting the safety profile of dabigatran etexilate. Study results were published in the New England Journal of Medicine (NEJM). 

ESUS is a type of cryptogenic stroke that accounts for one in six ischaemic strokes. After ESUS, most patients are treated with anti-platelet therapy, such as ASA, but one in three go on to experience a recurrent stroke within five years.

Pradaxa does not currently hold any regulatory approval for treating ESUS.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact